FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891359906> ?p ?o ?g. }

• W2891359906 endingPage "408" @default.
• W2891359906 startingPage "399" @default.
• W2891359906 abstract "Tumor microenvironment (TME) and associated multiple factors are found to contribute to the failures in cancer therapies, including chemo- and immunotherapy. Here we report a new multimodal strategy that uses a bioreactive multifunctional hybrid polymer-lipid encapsulated manganese dioxide nanoparticle (PLMD NP) system to remodel the TME, suppress drug resistance factors, reverse immunosuppressive conditions, and enhance chemotherapy efficacy.The influence of PLMD NPs on enhancing cellular uptake in EMT6 mouse breast cancer cells and tumor penetration of doxorubicin (DOX) in EMT6 orthotopic breast tumor mouse model was evaluated using confocal microscopy (n = 3-4). Immunohistochemistry was employed to examine the effect of PLMD NPs on downregulating hypoxia-induced drug resistance proteins and anticancer activity of DOX (n = 3-4). The efficacy of the combination therapy with PLMD NPS and DOX was assessed in murine EMT6 (n = 15-23) and 4T1 (n = 7) orthotopic breast tumor mouse models. Rechallenge and splenocyte transfer were performed to validate the stimulation of adaptive tumor immunity in the surviving mice.PLMD NPs enhanced intratumoral penetration and efficacy of DOX, and reduced intratumoral expression of P-glycoprotein, p53, and carbonic anhydrase IX by 74.5%, 38.0%, and 58.8% vs saline control, respectively. Combination treatment with PLMD NPs and DOX increased the number of tumor-infiltrated CD8+ T cells and resulted in up to 60.0% complete tumor regression. Of naïve mice (n = 7) that received splenocytes from the PLMD+DOX-treated surviving mice, 57.1% completely suppressed tumor growth whereas 100% of mice that received splenocytes from DOX-treated mice (n = 3) and the control group (n = 7) showed rapid tumor growth.The clinically suitable PLMD NPs can effectively downregulate TME-associated drug resistance and immunosuppression. The combination therapy with PLMD NPs and DOX is a multimodal and translational treatment approach for enhancing chemotherapeutic efficacy and boosting antitumor immunity." @default.
• W2891359906 created "2018-09-27" @default.
• W2891359906 creator A5029032414 @default.
• W2891359906 creator A5049058098 @default.
• W2891359906 creator A5060040461 @default.
• W2891359906 creator A5062977227 @default.
• W2891359906 creator A5063776390 @default.
• W2891359906 creator A5066716873 @default.
• W2891359906 creator A5073288648 @default.
• W2891359906 creator A5079349442 @default.
• W2891359906 creator A5080235829 @default.
• W2891359906 creator A5080698627 @default.
• W2891359906 date "2018-09-14" @default.
• W2891359906 modified "2023-10-11" @default.
• W2891359906 title "Combining Tumor Microenvironment Modulating Nanoparticles with Doxorubicin to Enhance Chemotherapeutic Efficacy and Boost Antitumor Immunity" @default.
• W2891359906 cites W1006554241 @default.
• W2891359906 cites W10911041 @default.
• W2891359906 cites W1483546674 @default.
• W2891359906 cites W1984484036 @default.
• W2891359906 cites W1997238548 @default.
• W2891359906 cites W2000798536 @default.
• W2891359906 cites W2017709634 @default.
• W2891359906 cites W2029325271 @default.
• W2891359906 cites W2030833199 @default.
• W2891359906 cites W2035566116 @default.
• W2891359906 cites W2037801848 @default.
• W2891359906 cites W2038636572 @default.
• W2891359906 cites W2049253717 @default.
• W2891359906 cites W2049491375 @default.
• W2891359906 cites W2052874737 @default.
• W2891359906 cites W2059409197 @default.
• W2891359906 cites W2064876347 @default.
• W2891359906 cites W2066379425 @default.
• W2891359906 cites W2081820338 @default.
• W2891359906 cites W2111722444 @default.
• W2891359906 cites W2112727616 @default.
• W2891359906 cites W2114977287 @default.
• W2891359906 cites W2115749410 @default.
• W2891359906 cites W2116369224 @default.
• W2891359906 cites W2121666843 @default.
• W2891359906 cites W2123318646 @default.
• W2891359906 cites W2125257427 @default.
• W2891359906 cites W2126882378 @default.
• W2891359906 cites W2128565827 @default.
• W2891359906 cites W2131783235 @default.
• W2891359906 cites W2139643093 @default.
• W2891359906 cites W2140380746 @default.
• W2891359906 cites W2142935250 @default.
• W2891359906 cites W2146037312 @default.
• W2891359906 cites W2153932922 @default.
• W2891359906 cites W2153949698 @default.
• W2891359906 cites W2158545805 @default.
• W2891359906 cites W2161665929 @default.
• W2891359906 cites W2165334726 @default.
• W2891359906 cites W2173452685 @default.
• W2891359906 cites W2309280425 @default.
• W2891359906 cites W2314057593 @default.
• W2891359906 cites W2417973730 @default.
• W2891359906 cites W2490141287 @default.
• W2891359906 cites W2528843175 @default.
• W2891359906 cites W2536322725 @default.
• W2891359906 cites W2555883270 @default.
• W2891359906 cites W2586380775 @default.
• W2891359906 cites W2597613988 @default.
• W2891359906 cites W2612358593 @default.
• W2891359906 cites W87335445 @default.
• W2891359906 doi "https://doi.org/10.1093/jnci/djy131" @default.
• W2891359906 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30239773" @default.
• W2891359906 hasPublicationYear "2018" @default.
• W2891359906 type Work @default.
• W2891359906 sameAs 2891359906 @default.
• W2891359906 citedByCount "47" @default.
• W2891359906 countsByYear W28913599062018 @default.
• W2891359906 countsByYear W28913599062019 @default.
• W2891359906 countsByYear W28913599062020 @default.
• W2891359906 countsByYear W28913599062021 @default.
• W2891359906 countsByYear W28913599062022 @default.
• W2891359906 countsByYear W28913599062023 @default.
• W2891359906 crossrefType "journal-article" @default.
• W2891359906 hasAuthorship W2891359906A5029032414 @default.
• W2891359906 hasAuthorship W2891359906A5049058098 @default.
• W2891359906 hasAuthorship W2891359906A5060040461 @default.
• W2891359906 hasAuthorship W2891359906A5062977227 @default.
• W2891359906 hasAuthorship W2891359906A5063776390 @default.
• W2891359906 hasAuthorship W2891359906A5066716873 @default.
• W2891359906 hasAuthorship W2891359906A5073288648 @default.
• W2891359906 hasAuthorship W2891359906A5079349442 @default.
• W2891359906 hasAuthorship W2891359906A5080235829 @default.
• W2891359906 hasAuthorship W2891359906A5080698627 @default.
• W2891359906 hasConcept C121608353 @default.
• W2891359906 hasConcept C126322002 @default.
• W2891359906 hasConcept C189976730 @default.
• W2891359906 hasConcept C203014093 @default.
• W2891359906 hasConcept C2776107976 @default.
• W2891359906 hasConcept C2776694085 @default.
• W2891359906 hasConcept C2777701055 @default.
• W2891359906 hasConcept C2779256057 @default.
• W2891359906 hasConcept C2781303535 @default.

• next